RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop
Programmable RNA Medicines
prweb
2 hours ago
0 views
Under an ARPA-H pilot award of up to $4.4 million over one year, the PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genome CAMBRIDGE, Mass., Sept. 1, 2026...
Continue Reading
Sign up for FREE to read the full article and access 158K+ alternative investment headlines.